Posts by Team VIVA!
Immunise Australia Budget package designed to keep kids vaccinations up-to-date – June 9, 2015
The Federal Government’s $26 million Immunise Australia Budget package aims to ensure busy parents in local areas keep their children’s vaccinations up to date and to dispel immunisation myths. Local immunisation providers, such as GPs, will be given an incentive to identify children in their practice who are overdue for vaccinations to ensure their immunisations…
Read MoreAustralians returning & disposing 600 tonnes of unwanted medicines each year – June 5, 2015
A study published in Australian Prescriber on June 1, 2015 has found more than $2 million of public money is wasted each year with the return of more than 600 tonnes of medicines, many of which are still within their expiry dates, through the National Return and Disposal of Unwanted Medicines Program, since its inception…
Read MoreRedefining market access success with Reimbursography – June 5, 2015
There’s no better feeling when running a strategic health + wellness communications agency than to identify a need, and be able to deliver a solution. We get to do that today with the introduction of Reimbursography – a strategic communications programme that leverages country-specific access insights to shape the value context for reimbursement success. Reimbursography…
Read MoreMelanoma patients not attending recommended check-ups – June 4, 2015
New study data released by Australia’s largest melanoma research and treatment centre, Melanoma Institute Australia, reveals many early-stage melanoma patients are not fulfilling the recommended medical check-ups within the first year post- diagnosis. According to an article published in Australian Doctor (June 3, 2015), “only 34 per cent of stage I patients and 14 per…
Read MorePBAC advises biosimilar medicines suitable for substitution at pharmacy level – June 2, 2015
In late April, 2015, The Pharmaceutical Benefits Advisory Committee (PBAC) pledged to consider marking biosimilar medicines equivalent to originator medicines, to which they are referenced against in Australia. This process would involve “a flagging”, whereby the biosimilar would be compared to the originator, in order to identify any significant differences in clinical efficacy or safety.…
Read More